Amlodipine
Brand: Norvasc (US/EU) / Amlopres (IN) / Amlodip (BD)
Antihypertensive
Calcium channel blocker (Dihydropyridine)
Pharmacokinetics
| Half-life | 35 hours |
| Tmax | 8 h |
| Bioavailability | 65 % (approx) |
| Protein Binding | 98 % |
| Volume of Distribution | 21 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Slow onset and long duration due to high volume of distribution; once-daily dosing; safe in renal impairment; metabolized by CYP3A4. |
⚠️ Safety & Warnings
Severity: Mild
Adverse Effects:
Pedal edema, flushing, headache, dizziness, palpitations
Contraindications:
Severe hypotension, cardiogenic shock
Precautions:
Monitor for edema and reflex tachycardia; caution in severe hepatic impairment